1-20 of 152 Search Results for

*

Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Effects and Eradication of Mycoplasma Contamination on Patient-derived Colorectal Cancer Organoid Cultures

Divya L. Dayanidhi, Wylie K. Watlington, John B. Mantyh, Gabrielle Rupprecht, David S. Hsu
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (9): 1952–1958.
https://doi.org/10.1158/2767-9764.CRC-23-0109
Published: 27 September 2023
View article titled, Effects and Eradication of <em>Mycoplasma</em> Contamination on Patient-derived Colorectal Cancer Organoid Cultures
Open the PDF for Effects and Eradication of <em>Mycoplasma</em> Contamination on Patient-derived Colorectal Cancer Organoid Cultures in another window
Includes: Supplementary data
Journal Articles

DNA2 nuclease inhibition confers synthetic lethality in cancers with mutant p53 and synergizes with PARP inhibitors

Helena Folly-Kossi, Joshua D Graves, Lidija A. Wilhelms Garan, Fang-Tsyr Lin, Weei-Chin Lin
Journal: Cancer Research Communications
Cancer Research Communications (2023)
https://doi.org/10.1158/2767-9764.CRC-23-0166
Published: 27 September 2023
View article titled, DNA2 nuclease inhibition confers synthetic lethality in cancers with mutant p53 and synergizes with PARP inhibitors
Open the PDF for DNA2 nuclease inhibition confers synthetic lethality in cancers with mutant p53 and synergizes with PARP inhibitors in another window
Includes: Supplementary data
Journal Articles

Fusobacterium nucleatum Load Correlates with KRAS Mutation and Sessile Serrated Pathogenesis in Colorectal Adenocarcinoma

Koki Takeda, Minoru Koi, Yoshiki Okita, Sija Sajibu, Temitope O. Keku, John M. Carethers
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (9): 1940–1951.
https://doi.org/10.1158/2767-9764.CRC-23-0179
Published: 26 September 2023
View article titled, <em>Fusobacterium nucleatum</em> Load Correlates with <em>KRAS</em> Mutation and Sessile Serrated Pathogenesis in Colorectal Adenocarcinoma
Open the PDF for <em>Fusobacterium nucleatum</em> Load Correlates with <em>KRAS</em> Mutation and Sessile Serrated Pathogenesis in Colorectal Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer

Devra Olson, Janelle Taylor, Kelsi Willis, Kelly Hensley, Sean Allred, Margo Zaval, Lauren Farr, Robert Thurman, Nishi Jain, Renee Hein, Michelle Ulrich, Scott Peterson, Anita Kulukian
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (9): 1927–1939.
https://doi.org/10.1158/2767-9764.CRC-23-0302
Published: 25 September 2023
View article titled, HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
Open the PDF for HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Piperacetazine directly binds to the PAX3::FOXO1 fusion protein and inhibits its transcriptional activity.

Kay Nakazawa, Taryn Shaw, Young K Song, Marilyn Kouassi-Brou, Anna Molotkova, Purushottam B Tiwari, Hsien-Chao Chou, Xinyu Wen, Jun S. Wei, Emre Deniz, Jeffrey Toretsky, Charles Keller, Frederic G. Barr, Javed Khan, Aykut Üren
Journal: Cancer Research Communications
Cancer Research Communications (2023)
https://doi.org/10.1158/2767-9764.CRC-23-0119
Published: 21 September 2023
View article titled, Piperacetazine directly binds to the PAX3::FOXO1 fusion protein and inhibits its transcriptional activity.
Open the PDF for Piperacetazine directly binds to the PAX3::FOXO1 fusion protein and inhibits its transcriptional activity. in another window
Includes: Supplementary data
Journal Articles

The inherited KRAS-variant as a biomarker of Cetuximab Response in NSCLC

Joanne B Weidhaas, Chen Hu, Ritsuko Komaki, Gregory A Masters, George R Blumenschein, Joe Y. Chang, Bo Lu, Adam P. Dicker, Jeffrey A Bogart, Yolanda I Garces, Samir Narayan, Clifford G. Robinson, Vivek S Kavadi, Joel S Greenberger, Christopher D Koprowski, James W. Welsh, Elizabeth Gore, Robert M MacRae, Rebecca Paulus, Jeffrey Bradley
Journal: Cancer Research Communications
Cancer Research Communications (2023)
https://doi.org/10.1158/2767-9764.CRC-23-0084
Published: 20 September 2023
View article titled, The inherited KRAS-variant as a biomarker of Cetuximab Response in NSCLC
Open the PDF for The inherited KRAS-variant as a biomarker of Cetuximab Response in NSCLC in another window
Includes: Supplementary data
Journal Articles

Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment

Jesus Amo-Aparicio, Adrian Dominguez, Shaikh M. Atif, Alberto Dinarello, Tania Azam, Kibrom M. Alula, Miles Piper, Christopher H. Lieu, Robert W. Lentz, Alexis D. Leal, Stacey M. Bagby, Wells A. Messersmith, Sana D. Karam, Charles A. Dinarello, Todd M. Pitts, Carlo Marchetti
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (9): 1899–1911.
https://doi.org/10.1158/2767-9764.CRC-23-0065
Published: 20 September 2023
View article titled, Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment
Open the PDF for Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment in another window
Includes: Supplementary data
Journal Articles

AKR1C3 Converts Castrate and Post-Abiraterone DHEA-S into Testosterone to Stimulate Growth of Prostate Cancer Cells via 5-Androstene-3β,17β-Diol

Andrea J. Detlefsen, Clementina A. Mesaros, Ling Duan, Trevor M. Penning
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (9): 1888–1898.
https://doi.org/10.1158/2767-9764.CRC-23-0235
Published: 19 September 2023
View article titled, AKR1C3 Converts Castrate and Post-Abiraterone DHEA-S into Testosterone to Stimulate Growth of Prostate Cancer Cells via 5-Androstene-3β,17β-Diol
Open the PDF for AKR1C3 Converts Castrate and Post-Abiraterone DHEA-S into Testosterone to Stimulate Growth of Prostate Cancer Cells via 5-Androstene-3β,17β-Diol in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors

Glenn J. Hanna, Anastasios Stathis, Elena Lopez-Miranda, Fabricio Racca, Doris Quon, Serge Leyvraz, Dagmar Hess, Bhumsuk Keam, Jordi Rodon, Myung-Ju Ahn, Hye Ryun Kim, Andreas Schneeweiss, Josep-Maria Ribera, Daniel DeAngelo, Jose Manuel Perez Garcia, Javier Cortes, Oliver Schönborn-Kellenberger, Dirk Weber, Pavel Pisa, Michael Bauer, Laura Beni, Maria Bobadilla, Raj Lehal, Michele Vigolo, Florian D. Vogl, Elena Garralda
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (9): 1853–1861.
https://doi.org/10.1158/2767-9764.CRC-23-0333
Published: 14 September 2023
View article titled, A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors
Open the PDF for A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors in another window
Includes: Supplementary data
Journal Articles

Targeting MALAT1 Augments Sensitivity to PARP Inhibition by Impairing Homologous Recombination in Prostate Cancer.

Anjali Yadav, Tanay Biswas, Ayush Praveen, Promit Ganguly, Ankita Bhattacharyya, Ayushi Verma, Dipak Datta, Bushra Ateeq
Journal: Cancer Research Communications
Cancer Research Communications (2023)
https://doi.org/10.1158/2767-9764.CRC-23-0089
Published: 13 September 2023
View article titled, Targeting MALAT1 Augments Sensitivity to PARP Inhibition by Impairing Homologous Recombination in Prostate Cancer.
Open the PDF for Targeting MALAT1 Augments Sensitivity to PARP Inhibition by Impairing Homologous Recombination in Prostate Cancer. in another window
Includes: Supplementary data
Journal Articles

Combined targeting of NAD biosynthesis and the NAD-dependent transcription factor C-terminal Binding Protein as a promising novel therapy for pancreatic cancer

M. Michael Dcona, Kranthi Kumar Chougoni, Diana T. Dcona, Jacqueline L West, Sahib J. Singh, Keith C. Ellis, Steven R. Grossman
Journal: Cancer Research Communications
Cancer Research Communications (2023)
https://doi.org/10.1158/2767-9764.CRC-22-0521
Published: 13 September 2023
View article titled, Combined targeting of NAD biosynthesis and the NAD-dependent transcription factor C-terminal Binding Protein as a promising novel therapy for pancreatic cancer
Open the PDF for Combined targeting of NAD biosynthesis and the NAD-dependent transcription factor C-terminal Binding Protein as a promising novel therapy for pancreatic cancer in another window
Includes: Supplementary data
Journal Articles

Surgical Inflammation Alters Immune Response to Intraoperative Photodynamic Therapy

Richard W. Davis, IV, Astero Klampatsa, Gwendolyn M. Cramer, Michele M. Kim, Joann M. Miller, Min Yuan, Cassandra Houser, Emma Snyder, Mary Putt, Sergei A. Vinogradov, Steven M. Albelda, Keith A. Cengel, Theresa M. Busch
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (9): 1810–1822.
https://doi.org/10.1158/2767-9764.CRC-22-0494
Published: 11 September 2023
View article titled, Surgical Inflammation Alters Immune Response to Intraoperative Photodynamic Therapy
Open the PDF for Surgical Inflammation Alters Immune Response to Intraoperative Photodynamic Therapy in another window
Includes: Supplementary data
Journal Articles

Nanoparticle Delivery of Immunostimulatory Alu RNA for Cancer Immunotherapy

Kyle M. Garland, Alexander J. Kwiatkowski, John T. Tossberg, Philip S. Crooke, III, Thomas M. Aune, John T. Wilson
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (9): 1800–1809.
https://doi.org/10.1158/2767-9764.CRC-22-0354
Published: 08 September 2023
View article titled, Nanoparticle Delivery of Immunostimulatory Alu RNA for Cancer Immunotherapy
Open the PDF for Nanoparticle Delivery of Immunostimulatory Alu RNA for Cancer Immunotherapy in another window
Includes: Supplementary data
Journal Articles

A Druggable FOXA1-Glucocorticoid Receptor Transcriptional Axis Drives Tumor Growth in a Subset of Non-Small Cell Lung Cancer

M. Dorso, Payal T. Patel, Aleksandr Pankov, Jacob A. Boyer, Rajesh K. Soni, Isabella S. Del Priore, Omar Hayatt, Amanda Kulick, Connor J. Hagen, Elisa de Stanchina, Melissa R. Junttila, Anneleen Daemen, Lori S. Friedman, Ronald C. Hendrickson, Sarat Chandarlapaty
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (9): 1788–1799.
https://doi.org/10.1158/2767-9764.CRC-23-0310
Published: 07 September 2023
View article titled, A Druggable FOXA1-Glucocorticoid Receptor Transcriptional Axis Drives Tumor Growth in a Subset of Non-Small Cell Lung Cancer
Open the PDF for A Druggable FOXA1-Glucocorticoid Receptor Transcriptional Axis Drives Tumor Growth in a Subset of Non-Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment

Jiahui Liu, Wenqiang Yan, Huishou Fan, Jingyu Xu, Lingna Li, Chenxing Du, Xuehan Mao, Yuting Yan, Yan Xu, Weiwei Sui, Shuhui Deng, Shuhua Yi, Kenneth C. Anderson, Lugui Qiu, Dehui Zou, Gang An
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (9): 1770–1780.
https://doi.org/10.1158/2767-9764.CRC-23-0185
Published: 06 September 2023
View article titled, Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
Open the PDF for Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment in another window
Includes: Supplementary data
Journal Articles

PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction In Vitro and In Vivo

Lisa Marie Fröhlich, Heike Niessner, Birgit Sauer, Sofie Kämereit, Eftychia Chatziioannou, Simon Riel, Tobias Sinnberg, Birgit Schittek
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (9): 1743–1755.
https://doi.org/10.1158/2767-9764.CRC-23-0101
Published: 05 September 2023
View article titled, PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <em>In Vitro</em> and <em>In Vivo</em>
Open the PDF for PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <em>In Vitro</em> and <em>In Vivo</em> in another window
Includes: Supplementary data
Journal Articles

Discovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor

Shruti Lal, Neil E. Bhola, Bee-Chun Sun, Yuping Chen, Tom Huang, Vivian Morton, Kevin X. Chen, Shanghua Xia, Haoyu Zhang, Nehal S. Parikh, Qiuping Ye, O. Petter Veiby, David I. Bellovin, Yuhua Ji
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (9): 1731–1742.
https://doi.org/10.1158/2767-9764.CRC-23-0304
Published: 01 September 2023
View article titled, Discovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor
Open the PDF for Discovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor in another window
Includes: Supplementary data
Journal Articles

Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens

Josep Tabernero, Philippe L. Bedard, Yung-Jue Bang, Maria Vieito, Min-Hee Ryu, Nathalie Fagniez, Mustapha Chadjaa, Christine Soufflet, Nina Masson, Anas Gazzah
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (8): 1662–1671.
https://doi.org/10.1158/2767-9764.CRC-23-0284
Published: 28 August 2023
View article titled, Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens
Open the PDF for Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens in another window
Includes: Supplementary data
Journal Articles

Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer

H. Catherine Wilbur, Jennifer N. Durham, Su Jin Lim, Katrina Purtell, Katherine M. Bever, Daniel A. Laheru, Ana De Jesus-Acosta, Nilofer S. Azad, Bradley Wilt, Luis A. Diaz, Dung T. Le, Hao Wang
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (8): 1672–1677.
https://doi.org/10.1158/2767-9764.CRC-23-0230
Published: 28 August 2023
View article titled, Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer
Open the PDF for Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

Multicellular Complex Tumor Spheroid Response to DNA Repair Inhibitors in Combination with DNA-damaging Drugs

Thomas S. Dexheimer, Nathan P. Coussens, Thomas Silvers, John Wright, Joel Morris, James H. Doroshow, Beverly A. Teicher
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (8): 1648–1661.
https://doi.org/10.1158/2767-9764.CRC-23-0193
Published: 25 August 2023
View article titled, Multicellular Complex Tumor Spheroid Response to DNA Repair Inhibitors in Combination with DNA-damaging Drugs
Open the PDF for Multicellular Complex Tumor Spheroid Response to DNA Repair Inhibitors in Combination with DNA-damaging Drugs in another window
Includes: Supplementary data